Hemogenyx Pharmaceuticals Share Discussion Threads

[badger60] 10/1/2022 06:03

Oi Pikey....did you know that your stock fluffer employer, SPAngel is named after kiddies sweets that were given to under 5 year olds by nonces to groom them....... "Spangles"
Careful who you work for Pikey, it's probably already rubbed off on you......

[checkricky] 09/1/2022 19:31

To stay up to date you can register with the link below for the H.C. Wainwright BIOCONNECT Virtual Conference Starts this Monday 10th January till the 13th January 2022

hxxps://my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&;rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118

As per last RNS:
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright Bioconnect Conference, in which the Company will be featured as a presenting company. The conference will be held on a virtual platform from January 10-13, 2022.


As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates to conference attendees.

If you are an institutional investor and would like to listen to the Company's presentation, please click on the following link to register for the conference: hxxps://hcwevents.com/bioconnect/.

The conference will feature corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link.


Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Bioconnect Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the development of medicines for the treatment of blood and autoimmune diseases."

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.



The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.



For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.


About H.C. Wainwright & Co.

H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

[checkricky] 09/1/2022 19:29

hxxps://my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&;rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118

[checkricky] 09/1/2022 19:28

worth a read investors.....

It's highlights the importance in CAR-T and effectiveness at targeting cancer cells. CAR-T will eventually be able to treat many types of cancer. I know it's early days but I hope HEMO become global players In treating patients which can only be a big positive...Researcher, Dr Claire Roddie, said the treatment was "absolutely transformative" and probably the biggest breakthrough in the past 20 years in malignant blood cancers. HEMO are onto a real big game changing treatment I just can not wait for things to get moving and HEMO will hopefully be global players in this field.. This share can't be sticking around 2p very long now. Next few months and coming weeks will be very interesting indeed... Hope your all having a great weekend

[checkricky] 09/1/2022 19:26

You can't blame the Mad Badger60 from Thailand his a psychopath suffering from chronic mental disorder that explains his abnormal unstable social behaviour.

[badger60] 09/1/2022 12:36

Oi Pikey....did you know that your stock fluffer employer, SPAngel is named after kiddies sweets that were given to under 5 year olds by nonces to groom them....... "Spangles"
Careful who you work for Pikey, it's probably already rubbed off on you......

[badger60] 09/1/2022 10:49

Pikey....I thought that you'd be out in the caravan nicking wheels off cars. That's what you usually do on the weekends, isn't it?

[badger60] 09/1/2022 10:44

Come back lunus1....all is forgiven..

[badger60] 09/1/2022 10:43

Pikey...read this again.I know it's difficult for you,being thick, so get your missus to read it to you when her bruises heal up....

Plenty of CAR-T competition, and MadVlad still trying to find the starting blocks on his 3 legged mouse. I would guess that most of the other 158 companies are well post IND, and at various stages of phase level development ................and have much more than 5 Mio quid to play with.


Since the first historic CAR-T approvals in 2017, Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Abecma (idecabtagene vicleucel), and Relma-cel (relmacabtagene autoleucel) have reached commercialization.

Not to mention those that have already reached commercialisation (listed above).

[checkricky] 09/1/2022 10:23

To stay up to date you can register with the link below for the H.C. Wainwright BIOCONNECT Virtual Conference Starts this Monday 10th January till the 13th January 2022

my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118

As per last RNS:
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce its participation in the H.C. Wainwright Bioconnect Conference, in which the Company will be featured as a presenting company. The conference will be held on a virtual platform from January 10-13, 2022.


As part of the Company's presentation, Dr. Vladislav Sandler, CEO of Hemogenyx Pharmaceuticals, will provide an overview of the Company's business and product candidates to conference attendees.

If you are an institutional investor and would like to listen to the Company's presentation, please click on the following link to register for the conference: hxxps://hcwevents.com/bioconnect/.

The conference will feature corporate presentations and panels both live and on-demand. Dr. Sandler's presentation is accessible using a webcast link.


Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "Our presentation at the H.C. Wainwright Bioconnect Investment Conference provides the Company with a great opportunity to inform the investment community about our achievements and increase the Company's visibility globally. It also allows us to further establish Hemogenyx Pharmaceuticals as a leader in the development of medicines for the treatment of blood and autoimmune diseases."

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.



The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.



For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.


About H.C. Wainwright & Co.

H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

[checkricky] 09/1/2022 10:13

hxxps://my.ct.events/register.aspx?meid=22d2962c-a482-43a2-8aad-53f12bd1b3da&;rpid=41d6be82-5fdd-4e3a-b857-a774c4e1a118

[checkricky] 09/1/2022 10:00

worth a read investors.....

It's highlights the importance in CAR-T and effectiveness at targeting cancer cells. CAR-T will eventually be able to treat many types of cancer. I know it's early days but I hope HEMO become global players In treating patients which can only be a big positive...Researcher, Dr Claire Roddie, said the treatment was "absolutely transformative" and probably the biggest breakthrough in the past 20 years in malignant blood cancers. HEMO are onto a real big game changing treatment I just can not wait for things to get moving and HEMO will hopefully be global players in this field.. This share can't be sticking around 2p very long now. Next few months and coming weeks will be very interesting indeed... Hope your all having a great weekend

[checkricky] 09/1/2022 09:57

You can't blame the Mad Badger60 from Thailand his a psychopath suffering from chronic mental disorder that explains his abnormal unstable social behaviour.

[badger60] 09/1/2022 06:30

Pikey

Plenty of CAR-T competition, and MadVlad still trying to find the starting blocks on his 3 legged mouse. I would guess that most of the other 158 companies are well post IND, and at various stages of phase level development ................and have much more than 5 Mio quid to play with.


Since the first historic CAR-T approvals in 2017, Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Abecma (idecabtagene vicleucel), and Relma-cel (relmacabtagene autoleucel) have reached commercialization.

Not to mention those that have already reached commercialisation (listed above).

[badger60] 09/1/2022 06:30

Pikey

Plenty of CAR-T competition, and MadVlad still trying to find the starting blocks on his 3 legged mouse. I would guess that most of the other 158 companies are well post IND, and at various stages of phase level development ................and have much more than 5 Mio quid to play with.


Since the first historic CAR-T approvals in 2017, Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Abecma (idecabtagene vicleucel), and Relma-cel (relmacabtagene autoleucel) have reached commercialization.

Not to mention those that have already reached commercialisation (listed above).

[badger60] 09/1/2022 05:32

Pikey.....fwiw my sale of Hemocasino was in response to Linus posting lies from the company on BBS.....The share price was immaterial.......